Ann Radiat Ther Oncol | Volume 1, Issue 1 | Mini Review | Open Access
Antonio Cassio Assis Pellizzon*
Department of Radiation Oncology, AC Camargo Cancer Center, Sao Paulo, Brazil
*Correspondance to: Antonio Cassio Assis Pellizzon
Fulltext PDFHistiocytic sarcoma (HS) is an extremely rare neoplasia, of hematopoietic origin that accounts for less than 1% of hematologic malignancies. HS can be localized or disseminated and the majority of lesions are reported presenting at extra-nodal sites, most frequently in the soft tissues and skin. Most patients presenting HS are being treated on an individual basis and the outcomes are still poor, especially in those with advanced or disseminated disease. There is no standard treatment recommended for HS. The treatment protocols available in the literature are diverse, with most patients being treated on an individual basis. Surgery and/or chemotherapy are the most commonly employed treatments, but radiotherapy seems to be an effective option in patients with localized disease.
Pellizzon ACA. Histiocytic Sarcoma a Rare Neoplasia. Ann Radiat Ther Oncol. 2017; 1(1): 1004.